AIM ImmunoTech Inc. (NYSE American: AIM) announced it has entered into agreements for a $2.4 million financing consisting of a registered direct offering and concurrent private placement. The company will sell 7,519,351 shares of common stock at $0.325 per share through the registered offering.

In the concurrent private placement, AIM ImmunoTech will issue Series I warrants to purchase up to 15,038,702 shares of common stock. The warrants carry an exercise price of $0.325 per share, require stockholder approval to exercise, and expire five years from the initial exercise date.

Ladenburg Thalmann & Co. Inc. serves as the exclusive placement agent for the offering, which is expected to close on or about May 21, 2026, subject to customary closing conditions.

The company stated it intends to use the net proceeds for manufacturing clinical drug supply, planned Phase 3 clinical trial activities, and working capital purposes.

The common stock offering is being conducted under the company's shelf registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission on July 3, 2025. The warrants will be issued through a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D.

AIM ImmunoTech develops therapeutics for cancers, immune disorders and viral diseases. The company's lead product candidate is Ampligen, described as a dsRNA and TLR3 agonist immunomodulator currently in clinical trials.